AstraZeneca: “FARXIGA approved in the US for the treatment of heart failure in patients with heart failure with reduced ejection fraction,” “Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction,” “What can I expect to pay for Farxiga?”
Deepak Bhatt, MD, executive director, interventional cardiovascular programs, Brigham and Women’s Hospital Heart & Vascular Center.
Cardiovascular Diabetology: “Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.”
CDC: “Vaginal Candidiasis.”
DiaTribe: “FDA Approves New Once-Daily Pill for Type 2 Diabetes: Steglatro.”
FDA: “FDA Approves new treatment for a type of heart failure,” “FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR),” “Prescribing Information: Farxiga,” “Sodium-glucose cotransporter-2 (SGLT2) inhibitors.”
Mayo Clinic: “Heart failure with preserved ejection fraction (HFpEF): More than diastolic dysfunction.”
Mount Sinai: “EMPEROR-HF: A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic heart failure with reduced ejection fraction (HFrEF).”
The New England Journal of Medicine: “Dapagliflozin in patients with heart failure and reduced ejection fraction.”
News release, AstraZeneca.
Kimberly O’Grady, media relations, AstraZeneca.
Wilson Tang, MD, heart failure specialist; director, heart failure research, Cleveland Clinic Heart & Vascular Institute.
U.S. National Library of Medicine: “Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure (DELIVER).”
UW Health: “Heart failure with reduced ejection fraction (Systolic heart failure).”
View original article here Source